Article

CIBA Vision alleges Vistakon violated lens patents

Atlanta—CIBA Vision Corp. said it is asking a federal judge in Florida to block Johnson & Johnson's Vistakon division from making, selling, and distributing silicone hydrogel contact lenses that it claims infringe upon its patents.

Atlanta-CIBA Vision Corp. said it is asking a federal judge in Florida to block Johnson & Johnson's Vistakon division from making, selling, and distributing silicone hydrogel contact lenses that it claims infringe upon its patents.

The motion seeks a temporary restraining order to block the planned U.S. launch of Vistakon's AcuVue Oasys lenses, which were introduced in Europe in April and due in U.S. eye-care professionals' offices this month.

A hearing was scheduled for Aug. 9 in the Federal District Court for the Middle District of Florida, according to CIBA Vision spokeswoman Kristie Madara.

"Ultimately, in a full trial on the merits, CIBA Vision will seek to prevent J&J/Vistakon permanently from infringing on these proprietary intellectual property rights," the company said.

Vistakon officials said their product does not infringe on the CIBA patent, and called the Nicolson patents "invalid and unenforceable." Vistakon had filed a lawsuit in February seeking a ruling on the patents.

"We are very excited about the U.S. introduction of AcuVue Oasys, and encourage eye-care professionals not to let CIBA's recent filing of this disputed motion affect adoption of AcuVue Oasys," Vistakon said in a prepared statement.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.